Bou Zerdan Maroun, Al Hassan Sally, Shaker Waleed, El Hajjar Rayan, Allam Sabine, Bou Zerdan Morgan, Naji Amal, Zeineddine Nabil
Department of Internal Medicine, SUNY Upstate Medical University, Syracuse, NY, USA.
These authors contributed equally to this article.
J Clin Med Res. 2022 Jul;14(7):251-259. doi: 10.14740/jocmr4764. Epub 2022 Jul 29.
Carbapenem resistance, an emerging global health problem, compromises the treatment of infections caused by nosocomial pathogens. Preclinical and clinical trials demonstrate that a new generation of carbapenemases inhibitors, together with the recently approved avibactam, relebactam and vaborbactam, would address this resistance. Our review summarizes the latest developments related to carbapenemase inhibitors synthesized to date, as well as their spectrum of activity and their current stage of development. A particular focus will be on β-lactam/β-lactamase inhibitor combinations that could potentially be used to treat infections caused by carbapenemase-producer pathogens. These new combinations mark a critical step forward the fight against antimicrobial resistance.
碳青霉烯耐药性是一个新出现的全球健康问题，它会影响医院病原体引起的感染的治疗。临床前和临床试验表明，新一代碳青霉烯酶抑制剂与最近获批的阿维巴坦、瑞来巴坦和瓦泊巴坦一起，将解决这种耐药性问题。我们的综述总结了迄今为止合成的碳青霉烯酶抑制剂的最新进展，以及它们的活性谱和当前的开发阶段。特别关注的将是可能用于治疗由产碳青霉烯酶病原体引起的感染的β-内酰胺/β-内酰胺酶抑制剂组合。这些新组合标志着在抗击抗菌药物耐药性方面向前迈出了关键一步。
